Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Imaging of Hepatocellular Carcinoma With 18F-FSPG
NCT02379377Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Florilglutamic acid F-18 in hepatocellular carcinoma (HCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: 18F-FSPG PET standardized uptake value (SUV), 11C-acetate standardized uptake value (SUV) and 8 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
Florilglutamic acid F-18
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02379377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02379377.